ArticleExperimental and therapeutic medicine2015
Association between low expression levels of interleukin-9 and colon cancer progression.
Article in Experimental and therapeutic medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Th9 cells at the intersection of IBD and colorectal cancer: a context-dependent factor in carcinogenesis.Inflammation and regeneration · 2026Review
- Serum Cytokine Profiles Associated with Inflammation and Tumor Progression in Crohn's Disease and Colorectal Cancer.International journal of molecular sciences · 2026Article
- Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes.Journal for immunotherapy of cancer · 2026Article
- Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using LuminexCancer biomarkers : section A of Disease markers · 2025Article
- Interaction of S100A6 Protein with the Four-Helical Cytokines.Biomolecules · 2023Article
- The Dichotomy of Interleukin-9 Function in the Tumor Microenvironment.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2023Review
- Article
- Review
- The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.Frontiers in immunology · 2022Review
- Systemic Interleukins' Profile in Early and Advanced Colorectal Cancer.International journal of molecular sciences · 2021Review
- Expression and clinical significance of interleukin-9 in renal tumors.Translational andrology and urology · 2020Article
- The Role of Interleukin-9 in Cancer.Pathology oncology research : POR · 2020Review
- Significant and Conflicting Correlation of IL-9 WithFrontiers in immunology · 2020Observational
- The dichotomous function of interleukin-9 in cancer diseases.Journal of molecular medicine (Berlin, Germany) · 2019Review
- IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor MicroenvironmentTechnology in cancer research & treatment · 2019Article
- TFrontiers in oncology · 2019Review
- [Expression of interleukin-9 in colon cancer tissues and its clinical significance].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
- Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells.Immune network · 2018Article
- Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities.Oncology reports · 2017Article
- Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis.BioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although interleukin (IL)-9 has been extensively studied in inflammation and autoimmune diseases, the expression level of IL-9 in colon cancer and its clinical significance are less well established. In total, 15 healthy donors (HDs) and 60 patients who had been diagnosed with colon cancer that had undergone a surgical resection were enrolled in the study. The plasma levels of IL-9 in the HDs and cancer patients were detected by the liquid chip technique, while the expression levels of IL-9 in the colon cancer tissues and normal tissues were analyzed using immunohistochemistry (IHC) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Finally, the difference in the expression levels of IL-9 between the patients classified as tumor-node-metastasis stage I-II and stage III-IV was compared. The results demonstrated that the plasma levels of IL-9 in the patients with colon cancer were significantly lower when compared with the HDs (1.29 vs. 2.53 pg/ml, P<0.05). Furthermore, according to the IHC and RT-qPCR results, low expression levels of IL-9 were observed in the colon cancer tissues when compared with the normal tissues (P<0.05). With regard to the plasma and tumor tissue samples, patients diagnosed with stage III-IV colon cancer expressed lower levels of IL-9 compared with the stage I-II patients (P<0.05). In conclusion, low expression levels of IL-9 were observed in the tissue and plasma samples collected from the colon cancer patients, and the decreased expression of IL-9 was shown to correlate with colon cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.